ストックスクリーナーアプリを入手
2.51
0.79%
-0.02
前日終値:
$2.53
開ける：
$2.52
24時間の取引高:
272.35K
Relative Volume:
0.58
時価総額：
$124.09M
収益：
$226.63M
当期純損益:
$15.38M
株価収益率:
-50.20
EPS:
-0.05
ネットキャッシュフロー:
$35.61M
1週間 パフォーマンス:
+8.19%
1か月 パフォーマンス:
-6.86%
6か月 パフォーマンス:
-49.80%
1年 パフォーマンス:
-17.97%
1日の値動き範囲:
$2.45
$2.5762
1週間の範囲:
$2.25
$2.63
52週間の値動き範囲:
$2.13
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
名前
Puma Biotechnology Inc
セクター
電話
(424) 248-6500
住所
10880 WILSHIRE BLVD., LOS ANGELES, CA
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-28 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Underperform |
| 2019-10-08 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-10 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-01-17 | 開始されました | Leerink Partners | Mkt Perform |
| 2019-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-11-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-11-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 開始されました | Goldman | Sell |
| 2018-05-11 | 繰り返されました | Stifel | Buy |
| 2017-11-10 | 繰り返されました | Citigroup | Buy |
| 2017-11-10 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 繰り返されました | Stifel | Buy |
| 2017-09-11 | 繰り返されました | Credit Suisse | Outperform |
| 2017-07-10 | 再開されました | Leerink Partners | Outperform |
| 2017-06-06 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 繰り返されました | RBC Capital Mkts | Sector Perform |
すべてを表示
Puma Biotechnology Inc (PBYI) 最新ニュース
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment? - Simply Wall St
Puma Biotechnology Inc [NASDAQ: PBYI] Sees Decrease in Stock Value - Knox Daily
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - sharewise
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Financial Analysis: Puma Biotechnology Inc (PBYI)’s Ratios Unveil Key Insights - The Dwinnex
Was there any good news for Puma Biotechnology Inc (PBYI) stock in the last session? - US Post News
Q1 2026 EPS Estimates for Puma Biotechnology, Inc. Boosted by Analyst (NASDAQ:PBYI) - MarketBeat
Zacks Research Analysts Decrease Earnings Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Market Momentum: Puma Biotechnology Inc (PBYI) Registers a 4.33 Increase, Closing at 2.65 - The Dwinnex
Puma Biotech confirms court ruling on patent invalidity, disagrees with verdict - MSN
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop - Simply Wall St
Puma Biotech patent claims partially invalidated in court - Investing.com
Puma Biotech patent claims partially invalidated in court By Investing.com - Investing.com India
Puma Biotech patent claims partially invalidated in court By Investing.com - Investing.com Australia
Puma Biotech confirms court ruling on patent dispute with AstraZeneca - Seeking Alpha
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso - MSN
Post-Trade Analysis: Puma Biotechnology Inc (PBYI) Slides -24.79, Closing at 2.71 - The Dwinnex
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso - Seeking Alpha
Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Michael Patrick Miller Sells 23,358 Shares of Stock - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $81,519.42 in Stock - MarketBeat
Puma Biotechnology director sells over $81k in company stock - Investing.com
Puma Biotechnology director sells over $81k in company stock By Investing.com - Investing.com UK
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - Defense World
Vanguard Group Inc. Reduces Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Vanguard Group Inc. - MarketBeat
Puma Biotechnology's (NASDAQ:PBYI) Earnings Offer More Than Meets The Eye - Yahoo Finance
Puma Biotech prevails in patent suit against AstraZeneca - Investing.com
Puma Biotech prevails in patent suit against AstraZeneca - Investing.com India
Puma Biotech prevails in patent suit against AstraZeneca By Investing.com - Investing.com UK
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.com - Defense World
Following a 1.5% decline over last year, recent gains may please Puma Biotechnology, Inc. (NASDAQ:PBYI) institutional owners - Simply Wall St
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Puma Biotechnology (NASDAQ:PBYI) Upgraded by StockNews.com to "Strong-Buy" - MarketBeat
Citigroup upgrades Puma Biotechnology Inc (PBYI) stock to a Buy - Knox Daily
Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results - Defense World
HC Wainwright Reiterates Buy Rating for Puma Biotechnology (NASDAQ:PBYI) - Defense World
Puma Biotechnology Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology (NASDAQ:PBYI) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Analysts Have Been Trimming Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target After Its Latest Report - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Puma Biotechnology reported a total revenue reaching $47.1 million - Investing.com Canada
Earnings call: Puma Biotechnology reported a total revenue reaching $47.1 million - Investing.com UK
Lazard Asset Management LLC Acquires 48,520 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected - MSN
Puma Biotechnology (NASDAQ:PBYI) Rating Reiterated by HC Wainwright - MarketBeat
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected - Yahoo Finance
Analyzing Pacira BioSciences (NASDAQ:PCRX) & Puma Biotechnology (NASDAQ:PBYI) - Defense World
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected - Zacks Investment Research
Puma Biotechnology Inc (PBYI) 財務データ
収益
当期純利益
現金流量
EPS
1.28%
1.94%
大文字化:
|
ボリューム (24 時間):